Excipient and Degrading

МО (12 мкг)" onmouseout="this.style.backgroundColor='fff'"day after completion of Surgical Intensive Care Unit leukapheresis should be performed during the period of growth in the number of neutrophils badge reader h109 / L to> 5.0 h109 / l, patients with severe hr.neytropeniyeyu (THN) - initial dose of 1.2 IU (12 mcg) / kg / day subcutaneously by injection once or multiple entries, with periodic or idiopathic neutropenia initial dose of 0.5 IU (5 mcg) / kg / day subcutaneously once or by multiple introductions; correction dose - filhrastym injected daily into a stable neutrophil count exceeded 1.5 h109 / l, and after reaching the therapeutic effect of determining the minimum effective daily dose to maintain this level, after 1-2 weeks of treatment the badge reader dose can be doubled or reduced by half, depending on the effect of therapy, then every 1 -2 weeks conducting individual dose adjustment to maintain the average number of neutrophils in the range from 1,5 h109 badge reader l to 10h109 / L; mobilization of peripheral blood stem cells (PSKK) in healthy donors for allogenic transplantation PSKK recommended dose - 1 million IU (10 mcg ) / kg / day by 24 hour p / w infusion or subcutaneously injected 1 p / day for 4-5 consecutive days; leukapheresis conduct of 5 th day AIDS-related Complex if necessary to 6-day to obtain 4h106 CD34 + -klityn/kh body weight recipient. Indications for use drugs: reducing the duration of neutropenia and reduced frequency febrylnoyi neutropenia in patients receiving cytotoxic chemotherapy of malignant diseases (except hr.miyeloleykozu and myelodysplastic s-m), reducing the duration of neutropenia in patients receiving therapy with miyeloablatyvnu following transplantation bone marrow mobilization of peripheral blood here cells in patients, severe hr.urodzhena, periodic or idiopathic neutropenia (absolute number of neutrophils? 0.5 h109 / l) in children and adults.